Baidu
map

内分泌科指南

订阅

MedSci主页 / 所有栏目 / 内分泌科指南

2020 TES临床实践指南：女性绝经后骨质疏松症的药物治疗（更新版）

2020-02-18 美国内分泌学会 J Clin Endocrinol Metab. 2020 Mar 1;105(3).

绝经后骨质疏松症药物治疗

2020年，美国内分泌学会(TES)更新发布了女性绝经后骨质疏松症的药物治疗指南，文章通过回顾meta分析和临床试验结果，主要评估了罗莫佐单抗的疗效。

中文标题：

2020 TES临床实践指南：女性绝经后骨质疏松症的药物治疗（更新版）

英文标题：

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update.

发布机构：

美国内分泌学会

发布日期：

2020-02-18

简要介绍：

2020年，美国内分泌学会(TES)更新发布了女性绝经后骨质疏松症的药物治疗指南，文章通过回顾meta分析和临床试验结果，主要评估了罗莫佐单抗的疗效。

 

拓展指南：与骨质疏松相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2020 TES临床实践指南：女性绝经后骨质疏松症的药物治疗（更新版）)] GetToolGuiderByIdResponse(projectId=1, id=e5a711c0018683ec, title=2020 TES临床实践指南：女性绝经后骨质疏松症的药物治疗（更新版）, enTitle=Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update., guiderFrom=J Clin Endocrinol Metab. 2020 Mar 1;105(3)., authorId=null, author=, summary=2020年，美国内分泌学会(TES)更新发布了女性绝经后骨质疏松症的药物治疗指南，文章通过回顾meta分析和临床试验结果，主要评估了罗莫佐单抗的疗效。 , cover=, journalId=null, articlesId=null, associationId=129, associationName=美国内分泌学会, associationIntro=美国内分泌学会（The Endocrine Society）成立于1916年，是激素研究和内分泌学临床实践世界最大、最古老，也是最活跃的机构，致力于提升公众和其他医务人员对于内分泌学的了解，提高内分泌学者在国家科研和医疗政策层面的影响。学会现拥有来自100多个国家的约14000名会员，遍布医学、分子生物学、细胞生物学、生物化学、生理学、基因学、免疫学、教育等相关领域，包括临床医生、研究员、教师、学生、内分泌学领域的相关专业人员。学会出版专业期刊和杂志，举办国际会议，为医师提供教育培训项目，发布临床实践指南，积极募集相关研究资助，推动相关政策发展。, copyright=0, guiderPublishedTime=Tue Feb 18 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<P>2020年，美国内分泌学会(TES)更新发布了女性绝经后骨质疏松症的药物治疗指南，文章通过回顾meta分析和临床试验结果，主要评估了罗莫佐单抗的疗效。 </P> <P> </P>拓展指南：<strong>与<font color=red>骨质疏松</font>相关指南：</strong><br><ul><li><a href="//m.sandwebs.com/guideline/show_article.do?id=9420f1c001865a79" title="2020 EMAS/IGCS立场声明：妇科癌症后绝经期管理—聚焦围绝经期综合征和骨质疏松" target=_blank>2020 EMAS/IGCS立场声明：妇科癌症后绝经期管理—聚焦围绝经期综合征和骨质疏松</a></li> <li><a href="//m.sandwebs.com/guideline/show_article.do?id=a742b1c0018581c6" title="骨质疏松症中西医结合诊疗指南" target=_blank>骨质疏松症中西医结合诊疗指南</a></li> <li><a href="//m.sandwebs.com/guideline/show_article.do?id=365601c0018a5eab" title="骨质疏松症康复指南" target=_blank>骨质疏松症康复指南</a></li> <li><a href="//m.sandwebs.com/guideline/show_article.do?id=cdbd91c00182223a" title="骨质疏松症：治疗的药物的非临床评价行业指南（FDA）" target=_blank>骨质疏松症：治疗的药物的非临床评价行业指南（FDA）</a></li> <li><a href="//m.sandwebs.com/guideline/show_article.do?id=b4d341c001810664" title="中国骨质疏松性骨折骨修复策略专家共识（2019）" target=_blank>中国骨质疏松性骨折骨修复策略专家共识（2019）</a></li> 更多信息请点击：<a href="//m.sandwebs.com/guideline/list.do?q=%E9%AA%A8%E8%B4%A8%E7%96%8F%E6%9D%BE" target=_blank>有关骨质疏松更多指南</a></ul>, tagList=[TagDto(tagId=27464, tagName=绝经后骨质疏松症), TagDto(tagId=1113, tagName=药物治疗)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=10, categoryName=骨科, tenant=100), CategoryDto(categoryId=21067, categoryName=梅斯医学-骨质疏松网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=1, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11015, appHits=471, showAppHits=34, pcHits=2402, showPcHits=9657, likes=16, shares=78, comments=14, approvalStatus=1, publishedTime=Mon Feb 24 23:55:00 CST 2020, publishedTimeString=2020-02-18, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Feb 24 23:55:00 CST 2020, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 21:28:18 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2020 TES临床实践指南：女性绝经后骨质疏松症的药物治疗（更新版）)])
2020 TES临床实践指南：女性绝经后骨质疏松症的药物治疗（更新版）
下载请点击：
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1204561, encodeId=5c9512045614e, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3bb2943679, createdName=55590550, createdTime=Mon Mar 21 10:49:04 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963676, encodeId=88b69636e654, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40035494998, createdName=missye, createdTime=Sat May 08 11:38:27 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953082, encodeId=f55c9530827c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ed65272472, createdName=14826aa5m92暂无昵称, createdTime=Thu Apr 01 16:00:40 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914355, encodeId=2e2a91435569, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6da35450839, createdName=ms2000000315755340, createdTime=Thu Jan 07 13:25:58 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895821, encodeId=0eed89582170, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=588c5430556, createdName=ms4000001185481331, createdTime=Sat Oct 31 09:49:38 CST 2020, time=2020-10-31, status=1, ipAttribution=)]
    2022-03-21 55590550

    实用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1204561, encodeId=5c9512045614e, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3bb2943679, createdName=55590550, createdTime=Mon Mar 21 10:49:04 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963676, encodeId=88b69636e654, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40035494998, createdName=missye, createdTime=Sat May 08 11:38:27 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953082, encodeId=f55c9530827c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ed65272472, createdName=14826aa5m92暂无昵称, createdTime=Thu Apr 01 16:00:40 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914355, encodeId=2e2a91435569, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6da35450839, createdName=ms2000000315755340, createdTime=Thu Jan 07 13:25:58 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895821, encodeId=0eed89582170, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=588c5430556, createdName=ms4000001185481331, createdTime=Sat Oct 31 09:49:38 CST 2020, time=2020-10-31, status=1, ipAttribution=)]
    2021-05-08 missye

    很实用

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1204561, encodeId=5c9512045614e, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3bb2943679, createdName=55590550, createdTime=Mon Mar 21 10:49:04 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963676, encodeId=88b69636e654, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40035494998, createdName=missye, createdTime=Sat May 08 11:38:27 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953082, encodeId=f55c9530827c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ed65272472, createdName=14826aa5m92暂无昵称, createdTime=Thu Apr 01 16:00:40 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914355, encodeId=2e2a91435569, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6da35450839, createdName=ms2000000315755340, createdTime=Thu Jan 07 13:25:58 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895821, encodeId=0eed89582170, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=588c5430556, createdName=ms4000001185481331, createdTime=Sat Oct 31 09:49:38 CST 2020, time=2020-10-31, status=1, ipAttribution=)]
    2021-04-01 14826aa5m92暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1204561, encodeId=5c9512045614e, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3bb2943679, createdName=55590550, createdTime=Mon Mar 21 10:49:04 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963676, encodeId=88b69636e654, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40035494998, createdName=missye, createdTime=Sat May 08 11:38:27 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953082, encodeId=f55c9530827c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ed65272472, createdName=14826aa5m92暂无昵称, createdTime=Thu Apr 01 16:00:40 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914355, encodeId=2e2a91435569, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6da35450839, createdName=ms2000000315755340, createdTime=Thu Jan 07 13:25:58 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895821, encodeId=0eed89582170, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=588c5430556, createdName=ms4000001185481331, createdTime=Sat Oct 31 09:49:38 CST 2020, time=2020-10-31, status=1, ipAttribution=)]
    2021-01-07 ms2000000315755340

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1204561, encodeId=5c9512045614e, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3bb2943679, createdName=55590550, createdTime=Mon Mar 21 10:49:04 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963676, encodeId=88b69636e654, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40035494998, createdName=missye, createdTime=Sat May 08 11:38:27 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953082, encodeId=f55c9530827c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ed65272472, createdName=14826aa5m92暂无昵称, createdTime=Thu Apr 01 16:00:40 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914355, encodeId=2e2a91435569, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6da35450839, createdName=ms2000000315755340, createdTime=Thu Jan 07 13:25:58 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895821, encodeId=0eed89582170, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=588c5430556, createdName=ms4000001185481331, createdTime=Sat Oct 31 09:49:38 CST 2020, time=2020-10-31, status=1, ipAttribution=)]
    2020-10-31 ms4000001185481331

    学习

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

双膦酸盐与狄诺塞麦治疗PMOP的“药物假期”EMAS立场声明要点解读

暂未更新 · 2018-08-20

Baidu
map
Baidu
map
Baidu
map